Navigation Links
Reduced POD linked to fatal asthma attacks

Asthmatic patients with reduced perception of dyspnoea (POD) may be at increased risk of experiencing a life-threatening exacerbation of their condition.// It was found that patients with low POD had significantly more emergency department visits, hospitalisations, fatal asthma attacks and deaths during a 2 year study period than those with normal dyspnoea perception.

The patients with low POD tended to be older, female and generally had suffered from asthma for a longer period of time than the patients with normal or high POD. Low POD patients also used less beta-agonist medication than high POD patients. Fatal or near-fatal asthma is not always accompanied by severe symptoms and, therefore, some patients may not seek appropriate assistance.

The researchers studied 113 patients with stable asthma attending an outpatient clinic. The patients were asked to regular follow-up every three months for up to 2 years and were required to comply with recording daily peak flow measurements and treatments on a diary card for the first month.

Researchers found that patients with low POD were more likely to suffer from fatal and near-fatal asthma attacks than those with high or normal POD.The researchers said that patients identified with low POD should be monitored carefully and more often, and should be educated in self-management.
'"/>




Page: 1

Related medicine news :

1. Reduced fertility in men who mountain bike
2. Reduced Fatigue Boosts Mental Health
3. Rejection Rate for Liver Transplants Patient Reduced
4. Calcium-Vitamin D Combo For Reduced Fracture Risk
5. Heart Disease In Women Can Be Reduced By Eating Grapes
6. Cholesterol; Can Be Reduced By Sunflower Seeds, and Pistachios
7. Snoring To Be Reduced By New Device Called True Sleep
8. Infectious Diseases Reduced in China
9. Death Risk Of Ovarian Cancer Reduced By Intraperitoneal Chemotherapy
10. Breast Cancer Treatment Reduced From Six Weeks To Five Days.
11. Chances Of Getting Cancer Can Be Reduced By Hysterectomy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: